LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis AG (NYSE: NVS), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NVS. The Company announced on September 20, 2017, that the European Commission (EC) approved Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Rydapt is also approved for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine response followed by Rydapt single-agent maintenance therapy, for adults with newly diagnosed acute myeloid leukemia, who are yet again, FLT3 mutation-positive. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NVS. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=NVS

Acute Myeloid Leukemia (AML)

AML is the most common acute leukemia, or blood cancer, in adults, which accounts for about 25% of all the adult leukemias worldwide, where the highest incidence rates occur in the US, Europe, and Australia, and also comes with the lowest survival rate for all adult leukemias. In the European Union (EU), there are more than 18,000 estimated new cases of AML diagnosed each year, of which one-third AML patients have a FLT3 mutation. FLT3 is a variant of a cell-surface receptor which accelerates the growth of certain blood cells. The FLT3 gene mutation can result in faster disease progression, higher relapse rates, and lower rates of survival than other forms of AML.

About Rydapt

Rydapt, also known as midostaurin, is an oral, targeted therapy that interferes with certain pathways that are involved in the growth, progression, and spread of cancer. Rydapt inhibits multiple kinases, including FLT3 which help regulate essential cell processes, thus interrupting cancer cells' ability to grow and multiply. Rydapt induces cell death in leukemic cells with FLT3 ITD or TKD mutant receptors, or in cells overexpressing FLT3 wildtype receptors.

This approval comes post the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on July 20, 2017, and applies to all 28 EU member states, Iceland, Liechtenstein, and Norway. Rydapt represents the first and only targeted therapy for FMS-like tyrosine kinase 3 (FLT3)-mutated AML and the only treatment for three subtypes of SM, collectively known as advanced SM, in the EU, all of which come with limited life expectancy and few treatment options. Rydapt is probably the first major advancement for the treatment of patients with newly diagnosed FLT3-mutated AML in more than 25 years.

Approval Data

The approval data for the newly diagnosed FLT3-mutated AML is based on data from the RATIFY trial, which was conducted in collaboration with the alliance for Clinical Trials in Oncology and 13 international groups. RATIFY is the largest trial to date which has been put to test among people with the FLT3-mutated AML, where the results of the trial were recently published in the New England Journal of Medicine. The study showed a reduction in the risk of death by 25% when Rydapt was used along with standard chemotherapy, against placebo plus standard chemotherapy. In order to enhance the potential of Rydapt in AML, Novartis announced that it plans a Phase-III study in newly diagnosed AML patients without a FLT3 mutation.

Last Close Stock Review

At the closing bell, on Thursday, September 21, 2017, Novartis' stock marginally dropped 0.98%, ending the trading session at $84.94. A total volume of 1.24 million shares have exchanged hands. The Company's stock price surged 1.71% in the last one month, 14.12% in the past six months, and 4.20% in the previous twelve months. Moreover, the stock rallied 16.61% since the start of the year. The stock is trading at a PE ratio of 31.00 and has a dividend yield of 3.20%. The stock currently has a market cap of $223.89 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily